Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-specific oral migraine preventive medication (OMPM) o...
Saved in:
Main Authors: | Stewart J Tepper (Author), Juanzhi Fang (Author), Lujia Zhou (Author), Pamela Vo (Author), Ahmad Abdrabboh (Author), Mrudula Glassberg (Author), Matias Ferraris (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
by: Ronan Mahon, et al.
Published: (2024) -
Erenumab efficacy predictors for chronic migraine
by: Nina V. Vashchenko
Published: (2022) -
Assessment and characteristics of Erenumab therapy on migraine management
by: Haitham Saeed, et al.
Published: (2022) -
Predictors of clinical response to erenumab in patients with migraine
by: Olga Lekontseva, et al.
Published: (2022) -
Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine
by: Po‐Wei Chen, et al.
Published: (2023)